ALK-Positive Non-Small Cell Lung Cancer Initial and continuing PBS authority application Supporting information form (PB156)

You must lodge this form for a patient starting initial or continuing Pharmaceutical Benefits Scheme (PBS) subsidised treatment with crizotinib for Stage IIIB (locally advanced) or Stage IV (metastatic) ALK-Positive non squamous type Non-Small Cell Lung Cancer (NSCLC) or not otherwise specified NSCLC.


Page last updated: 5 February 2016

This information was printed Friday 30 September 2016 from It may not include all of the relevant information on this topic. Please consider any relevant site notices at when using this material.